Levosimendan improves event free survival by 50 percent in end-stage heart ... RxPG NEWS In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease (CKD). Heart Failure 2013 is the main annual meeting of ... |
